Reduced Homogeneous Myocardial [18F]FDG Uptake in Routine PET/CT Studies as an Early Indicator of Chemotherapy-Induced Cardiotoxicity

被引：0

作者：

Palomino-Fernandez, David ^{[1
]}

Bueno, Hector ^{[2
,3
,4
,5
]}

Jimenez-Lopez-Guarch, Carmen ^{[2
,3
,4
]}

Moreno, Guillermo ^{[3
,6
]}

Seiffert, Alexander P. ^{[1
,7
]}

Gomez, Enrique J. ^{[1
,7
,8
]}

Gomez-Grande, Adolfo ^{[2
,9
]}

Sanchez-Gonzalez, Patricia ^{[1
,7
,8
]}

机构：

[1] Univ Politecn Madrid, Ctr Biomed Technol, Biomed Engn & Telemed Ctr, ETSI Telecomunicac, Madrid 28040, Spain

[2] UNIV COMPLUTENSE MADRID, Fac Med, MADRID 28040, Spain

[3] Hosp Univ 12 Octubre, Inst Invest Sanitaria Imas12, Dept Cardiol, Madrid 28041, Spain

[4] Ctr Invest Biomed Red Enfermedades Cardiovasc CIBE, Madrid 28029, Spain

[5] Ctr Nacl Invest Cardiovasc CNIC, Madrid 28029, Spain

[6] Univ Complutense Madrid, Fac Enfermeria Fisioterapia & Podol, Madrid 28040, Spain

[7] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Madrid 28041, Spain

[8] Inst Salud Carlos III, Ctr Invest Biomed Red Bioingn Biomat & Nanomed, Madrid 28029, Spain

[9] Hosp Univ 12 Octubre, Dept Nucl Med, Madrid 28041, Spain

来源：

APPLIED SCIENCES-BASEL | 2024年 / 14卷 / 24期

关键词：

F-18]FDG PET; myocardial metabolism; cardiotoxicity; cancer therapy-related cardiac dysfunction; radiomics; early diagnosis; FDG UPTAKE; CANCER; METABOLISM; MECHANISMS; TOXICITY; DISEASE;

D O I：

10.3390/app142411653

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

Cardiotoxicity refers to the damage induced by antineoplastic treatments, leading to various cardiovascular conditions. [F-18]FDG PET radiomics analysis could provide relevant information on early onset changes occurring in cardiac metabolism of chemotherapy-induced cardiotoxicity. Patients' sociodemographic data, cardiovascular risk factors, laboratory parameters, and left ventricle [F-18]FDG PET radiomic features are analyzed. The H-Rad index for the quantification of the heterogeneity of the metabolic uptake patterns is proposed. Statistical analysis is performed by separating patients according to the diagnosis of cancer therapy-related cardiac dysfunction (CTRCD). Baseline, intermediate, and end-of-treatment scans are evaluated as separate groups. Overall, CTRCD+ patients show lower overall mean standardized uptake values (SUVmean) compared to CTRCD- patients, with statistically significant differences between groups only observed in the intermediate PET study (p = 0.025). A total of 34 radiomic features show statistically significant differences between the CTRCD+ and CTRCD- groups in the intermediate imaging studies. In the CTRCD- group, greater overall heterogeneity of metabolic uptake is observed in the intermediate PET image compared to the CTRCD+ groups (p = 0.025). The assessment of CTRCD through [F-18]FDG PET radiomics analysis could be a potential tool for the identification of a predisposition to the later development of cardiac complications after cardiotoxic treatment.

引用

页数：13

共 45 条

[1] Miller K.D., Nogueira L., Mariotto A.B., Rowland J.H., Yabroff K.R., Alfano C.M., Jemal A., Kramer J.L., Siegel R.L., Cancer Treatment and Survivorship Statistics, 2019. CA, Cancer J. Clin, 69, pp. 363-385, (2019)
[2] Curigliano G., Lenihan D., Fradley M., Ganatra S., Barac A., Blaes A., Herrmann J., Porter C., Lyon A.R., Lancellotti P., Et al., Management of Cardiac Disease in Cancer Patients throughout Oncological Treatment: ESMO Consensus Recommendations, Ann. Oncol, 31, pp. 171-190, (2020)
[3] Lopez-Fernandez T., Martin Garcia A., Santaballa Beltran A., Montero Luis A., Garcia Sanz R., Mazon Ramos P., Velasco del Castillo S., Lopez de Sa Areses E., Barreiro-Perez M., Hinojar Baydes R., Et al., Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations, Rev. Española Cardiol, 70, pp. 474-486, (2017)
[4] Bhagat A., Kleinerman E.S., Anthracycline-Induced Cardiotoxicity: Causes, Mechanisms, and Prevention, Adv. Exp. Med. Biol, 1257, pp. 181-192, (2020)
[5] Herrmann J., Adverse Cardiac Effects of Cancer Therapies: Cardiotoxicity and Arrhythmia, Nat. Rev. Cardiol, 17, pp. 474-502, (2020)
[6] Curigliano G., Cardinale D., Dent S., Criscitiello C., Aseyev O., Lenihan D., Cipolla C.M., Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management. CA, Cancer J. Clin, 66, pp. 309-325, (2016)
[7] Novo G., Nugara C., Fava A., Mantero A., Citro R., Early Detection of Myocardial Damage: A Multimodality Approach, J. Cardiovasc. Echogr, 30, pp. S4-S10, (2020)
[8] Lyon A.R., Lopez-Fernande T., Couch L.S., Asteggiano R., Aznar M.C., Bergler-Klei J., Boriani G., Cardinale D., Cordoba R., Cosyns B., Et al., 2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the Task Force on Cardio-Oncology of the European Society of Cardiology (ESC), Eur. Heart J, 43, pp. 4229-
[9] Zito C., Longobardo L., Cadeddu C., Monte I., Novo G., Dell'oglio S., Pepe A., Madonna R., Tocchetti C.G., Mele D., Cardiovascular Imaging in the Diagnosis and Monitoring of Cardiotoxicity: Role of Echocardiography, J. Cardiovasc. Med, 17, pp. S45-S54, (2016)
[10] Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., Cohen V., Banchs J., Carver J.R., Wiegers S.E., Et al., Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated with Anthracyclines, Taxanes, and Trastuzumab, Circ. Cardiovasc. Imaging, 5, pp. 596-603, (2012)

← 1 2 3 4 5 →